Market Research Report
OTC Cold & Flu
|Published by||Nicholas Hall & Company||Product code||512739|
Delivery time: 1-2 business days
|OTC Cold & Flu|
|Published: August 3, 2017||Content info:||
This report is an in-depth exploration of the OTC Cold & Flu market, including Systemic cold & flu, Topical decongestants and Chest rubs & inhalants, plus VMS brands positioned for immunity, and includes coverage of 20 major markets from across the globe, with topline sales, brand performances, new developments, launches and A+P campaigns.
With full-year 2016 OTC sales from DB6 2017, it also includes case studies of key OTC Cold & Flu brands, highlighting success factors, sales, NPD and A+P activity, with forecasts sales for all categories and countries, plus predictions for the future.
With global sales of $10.7bn in 2016, the combined categories of Systemic cold & flu, Topical decongestants and Chest rubs & inhalants grew by 5.6% on the previous year, significantly outpacing the global OTC market (+4.3%).
The leading players in Cold & Flu† posted average growth of 3.3% in 2016, but this masks a diverse range of performances from players and their key brands. Discover how individual marketers and brands performed, both globally and in specific markets, and where the truly dynamic growth is coming from.
The report investigates immunity-boosting VMS brands, reviewing the OTC market for Immune supplements, Zinc supplements, Vitamin C, selected Multivitamins and Tonics & cure alls, among others. Have these preventive supplements impacted demand for self-care cold & flu treatments?
20 individual markets profiled in this report:
Categories covered by this report: